Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1972 4
1973 1
1974 5
1975 2
1977 1
1978 1
1979 3
1980 4
1981 5
1982 5
1983 5
1984 1
1985 2
1986 4
1987 4
1988 21
1989 6
1990 6
1991 13
1992 9
1993 11
1994 16
1995 16
1996 15
1997 11
1998 15
1999 20
2000 35
2001 25
2002 23
2003 16
2004 14
2005 18
2006 21
2007 23
2008 21
2009 24
2010 22
2011 20
2012 33
2013 28
2014 34
2015 35
2016 42
2017 47
2018 49
2019 51
2020 37
2021 50
2022 62
2023 57
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

886 results

Results by year

Filters applied: . Clear all
Page 1
Cardiomyopathies: An Overview.
Ciarambino T, Menna G, Sansone G, Giordano M. Ciarambino T, et al. Int J Mol Sci. 2021 Jul 19;22(14):7722. doi: 10.3390/ijms22147722. Int J Mol Sci. 2021. PMID: 34299342 Free PMC article. Review.
The search keywords were "cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy, arrhythmogenic cardiomyopathy (ARCV), takotsubo syndrome". RESULTS: Hypertrophic …
The search keywords were "cardiomyopathies, sudden cardiac arrest, dilated cardiomyopathy (DCM), hypertrophic cardiomyopath …
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P. Ommen SR, et al. Circulation. 2020 Dec 22;142(25):e533-e557. doi: 10.1161/CIR.0000000000000938. Epub 2020 Nov 20. Circulation. 2020. PMID: 33215938 Free article. Review.
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting do …
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorit …
Hypertrophic cardiomyopathy: part 1 - introduction, pathology and pathophysiology.
Varma PK, Neema PK. Varma PK, et al. Ann Card Anaesth. 2014 Apr-Jun;17(2):118-24. doi: 10.4103/0971-9784.129841. Ann Card Anaesth. 2014. PMID: 24732610 Review.
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with many genotype and phenotype variations. Earlier terminologies, hypertrophic obstructive cardiomyopathy and idiopathic hypertrophic sub-aortic stenosis are n …
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease with many genotype and phenotype variation …
Hypertrophic cardiomyopathy: a systematic review.
Maron BJ. Maron BJ. JAMA. 2002 Mar 13;287(10):1308-20. doi: 10.1001/jama.287.10.1308. JAMA. 2002. PMID: 11886323 Review.
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardiomyopathy (HCM), a genetic cardiac disease caused by a variety of mutations in genes encoding sarcomeric proteins and characterized by a …
CONTEXT: Throughout the past 40 years, a vast and sometimes contradictory literature has accumulated regarding hypertrophic cardio …
Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Management.
Lioncino M, Monda E, Verrillo F, Moscarella E, Calcagni G, Drago F, Marino B, Digilio MC, Putotto C, Calabrò P, Russo MG, Roberts AE, Gelb BD, Tartaglia M, Limongelli G. Lioncino M, et al. Heart Fail Clin. 2022 Jan;18(1):19-29. doi: 10.1016/j.hfc.2021.07.004. Epub 2021 Oct 25. Heart Fail Clin. 2022. PMID: 34776080 Free PMC article. Review.
Diagnosis of RASopathy can be triggered by clinical clues ("red flags") which may direct the clinician toward a specific gene test. Compared with sarcomeric hypertrophic cardiomyopathy, hypertrophic cardiomyopathy in RASopathies (R-HCM) is associated w …
Diagnosis of RASopathy can be triggered by clinical clues ("red flags") which may direct the clinician toward a specific gene test. Compared …
Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Ismayl M, Abbasi MA, Marar R, Geske JB, Gersh BJ, Anavekar NS. Ismayl M, et al. Curr Probl Cardiol. 2023 Jan;48(1):101429. doi: 10.1016/j.cpcardiol.2022.101429. Epub 2022 Sep 24. Curr Probl Cardiol. 2023. PMID: 36167226 Review.
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unchanged for decades until the recent introduction of mavacamten, a first-in-class cardiac myosin inhibitor. ...Compared to placebo, mavacamte …
Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy, yet pharmacological therapy has been unc …
Cardiology: hypertrophic cardiomyopathy.
Medical Masterclass contributors; Firth J. Medical Masterclass contributors, et al. Clin Med (Lond). 2019 Jan;19(1):61-63. doi: 10.7861/clinmedicine.19-1-61. Clin Med (Lond). 2019. PMID: 30651247 Free PMC article. Review. No abstract available.
The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy.
Finocchiaro G, Sheikh N, Biagini E, Papadakis M, Maurizi N, Sinagra G, Pelliccia A, Rapezzi C, Sharma S, Olivotto I. Finocchiaro G, et al. Heart Rhythm. 2020 Jan;17(1):142-151. doi: 10.1016/j.hrthm.2019.07.019. Epub 2019 Aug 10. Heart Rhythm. 2020. PMID: 31349064 Review.
To date, the ECG remains an irreplaceable first step when evaluating patients with hypertrophic cardiomyopathy (HCM) and an abnormal ECG may be the only manifestation of disease at an early stage. ...
To date, the ECG remains an irreplaceable first step when evaluating patients with hypertrophic cardiomyopathy (HCM) and an ab …
New perspectives on the prevalence of hypertrophic cardiomyopathy.
Semsarian C, Ingles J, Maron MS, Maron BJ. Semsarian C, et al. J Am Coll Cardiol. 2015 Mar 31;65(12):1249-1254. doi: 10.1016/j.jacc.2015.01.019. J Am Coll Cardiol. 2015. PMID: 25814232 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is an important genetic heart muscle disease for which prevalence in the general population has not been completely resolved. For the past 20 years, most data have supported the occurrence of HCM at about 1 in 500. However, t …
Hypertrophic cardiomyopathy (HCM) is an important genetic heart muscle disease for which prevalence in the general population …
Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Sebastian SA, Padda I, Lehr EJ, Johal G. Sebastian SA, et al. Am J Cardiovasc Drugs. 2023 Sep;23(5):519-532. doi: 10.1007/s40256-023-00599-0. Epub 2023 Aug 1. Am J Cardiovasc Drugs. 2023. PMID: 37526885 Review.
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradients and improve heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). Based on the REDWOOD-HC …
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradie …
886 results